DK496485A - Transformation af gaer-stammer af slaegten pichia - Google Patents

Transformation af gaer-stammer af slaegten pichia Download PDF

Info

Publication number
DK496485A
DK496485A DK496485A DK496485A DK496485A DK 496485 A DK496485 A DK 496485A DK 496485 A DK496485 A DK 496485A DK 496485 A DK496485 A DK 496485A DK 496485 A DK496485 A DK 496485A
Authority
DK
Denmark
Prior art keywords
genus pichia
treasures
year
transformation
yeast strains
Prior art date
Application number
DK496485A
Other languages
Danish (da)
English (en)
Other versions
DK496485D0 (da
Inventor
David Womack Stroman
James Michael Cregg
Michael Miller Harpold
George T Sperl
Original Assignee
Phillips Petroleum Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co
Publication of DK496485D0 publication Critical patent/DK496485D0/da
Publication of DK496485A publication Critical patent/DK496485A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Tires In General (AREA)
  • Cosmetics (AREA)
  • General Preparation And Processing Of Foods (AREA)
DK496485A 1984-10-30 1985-10-29 Transformation af gaer-stammer af slaegten pichia DK496485A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/666,579 US4879231A (en) 1984-10-30 1984-10-30 Transformation of yeasts of the genus pichia

Publications (2)

Publication Number Publication Date
DK496485D0 DK496485D0 (da) 1985-10-29
DK496485A true DK496485A (da) 1986-05-01

Family

ID=24674609

Family Applications (1)

Application Number Title Priority Date Filing Date
DK496485A DK496485A (da) 1984-10-30 1985-10-29 Transformation af gaer-stammer af slaegten pichia

Country Status (18)

Country Link
US (1) US4879231A (OSRAM)
EP (1) EP0183070B1 (OSRAM)
JP (1) JPH0681593B2 (OSRAM)
AT (1) ATE68204T1 (OSRAM)
AU (1) AU572353B2 (OSRAM)
CA (1) CA1297438C (OSRAM)
DE (1) DE3584353D1 (OSRAM)
DK (1) DK496485A (OSRAM)
ES (1) ES8609464A1 (OSRAM)
FI (1) FI94428C (OSRAM)
GR (1) GR852609B (OSRAM)
IE (1) IE58217B1 (OSRAM)
IL (1) IL76763A (OSRAM)
MX (1) MX430A (OSRAM)
NO (1) NO178975C (OSRAM)
PT (1) PT81402B (OSRAM)
SG (1) SG43092G (OSRAM)
ZA (1) ZA858180B (OSRAM)

Families Citing this family (466)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4885242A (en) * 1984-10-30 1989-12-05 Phillips Petroleum Company Genes from pichia histidine pathway and uses thereof
US4818700A (en) * 1985-10-25 1989-04-04 Phillips Petroleum Company Pichia pastoris argininosuccinate lyase gene and uses thereof
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA872534B (en) * 1986-05-08 1987-11-25 Phillips Petroleum Co Yeast production of streptokinase
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
IL89989A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
US5204252A (en) * 1989-02-08 1993-04-20 Henkel Research Corporation Candida tropicalis transformation system
WO1990009434A1 (en) * 1989-02-13 1990-08-23 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of superoxide dismutase in pichia pastoris yeast cells
US5254466A (en) * 1989-11-06 1993-10-19 Henkel Research Corporation Site-specific modification of the candida tropicals genome
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
WO1992013951A1 (en) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
AU661844B2 (en) * 1991-04-01 1995-08-10 Merck Sharp & Dohme Corp. Genes which influence (pichia) proteolytic activity, and uses therefor
US6872550B1 (en) * 1991-07-11 2005-03-29 Baxter Vaccine Ag Immunogenic formulation of OspC antigen vaccines for the prevention and treatment of lyme disease and recombinant methods for the preparation of such antigens
US5665600A (en) * 1991-09-18 1997-09-09 Research Corporation Technologies, Inc. Pichia pastoris linear plasmids and DNA fragments thereof
DK0643772T3 (da) 1992-06-03 1998-02-02 Genentech Inc Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
WO1994020631A2 (en) * 1993-03-03 1994-09-15 E.I. Du Pont De Nemours And Company Production of glycolate oxidase in methylotrophic yeast
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
PL183855B1 (pl) * 1994-10-18 2002-07-31 Corvas International Białko, cząsteczka cDNA, oligonukleotyd, kompozycja farmaceutyczna i środek farmaceutyczny do hamowania krzepnięcia krwi
DE69628652T3 (de) 1995-09-08 2012-05-03 Genentech, Inc. Vegf-verwandtes protein
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
JP2000500014A (ja) * 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
CA2241564C (en) 1996-01-08 2013-09-03 Genentech, Inc. Wsx receptor and ligands
US5736383A (en) * 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) * 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
MX9605082A (es) 1996-10-24 1998-04-30 Univ Autonoma De Nuevo Leon Levaduras metilotroficas modificadas geneticamente para la produccion y secrecion de hormona de crecimiento humano.
AU729158B2 (en) 1997-01-31 2001-01-25 Genentech Inc. O-fucosyltransferase
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
EP0973804B1 (en) 1997-04-07 2006-12-27 Genentech, Inc. Anti-vegf antibodies
EP1695985B1 (en) 1997-04-07 2011-03-09 Genentech, Inc. Methods for forming humanised antibodies by random mutagenesis
US6265186B1 (en) 1997-04-11 2001-07-24 Dsm N.V. Yeast cells comprising at least two copies of a desired gene integrated into the chromosomal genome at more than one non-ribosomal RNA encoding domain, particularly with Kluyveromyces
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
IL135704A (en) 1997-10-29 2008-04-13 Genentech Inc Method of diagnosing neoplastic cell growth by detection of the wnt-1 induced secreted polypeptide wisp-1
EP2033970A3 (en) 1997-10-29 2009-06-17 Genentech, Inc. Polypeptides and nucleic acids encoding the same
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
EP3112468A1 (en) 1998-05-15 2017-01-04 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
PT1076703E (pt) 1998-05-15 2007-10-10 Genentech Inc ''utilizações terapêuticas de polipéptido homólogos de il-17''
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6316245B1 (en) * 1998-09-16 2001-11-13 Biongene Co., Ltd. Mutant cells of Pichia
SI1135498T1 (sl) 1998-11-18 2008-06-30 Genentech Inc Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US6720174B1 (en) 1999-01-28 2004-04-13 Novozymes A/S Phytases
EP1978029A3 (en) 1999-06-15 2008-10-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
CH694589A5 (de) 1999-06-25 2005-04-15 Genentech Inc Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
WO2001029078A2 (en) * 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
CA2496312A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Colon tumour marker pro4799 polypeptides and nucleic acids encoding the same
EP2163625B1 (en) 1999-12-23 2014-05-21 Genentech, Inc. IL-17 and IL-17R homologous polypeptides and therapeutic uses thereof
WO2001077351A1 (en) * 2000-04-07 2001-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vectors and methods for dual protein expression in pichia pastoris and escherichia coli
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
EP2075253A1 (en) 2000-06-23 2009-07-01 Genentech, Inc. Compositions and methds for the diagnosis and treatment of disorders involving angiogensis
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US8697394B2 (en) * 2000-06-28 2014-04-15 Glycofi, Inc. Production of modified glycoproteins having multiple antennary structures
US7598055B2 (en) * 2000-06-28 2009-10-06 Glycofi, Inc. N-acetylglucosaminyltransferase III expression in lower eukaryotes
US7625756B2 (en) 2000-06-28 2009-12-01 GycoFi, Inc. Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
US7863020B2 (en) 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
DK1294910T3 (da) 2000-06-30 2009-03-02 Vib Vzw Protein glykosyleringsmodifikation i Pichia Pastoris
US7009045B2 (en) * 2000-07-14 2006-03-07 Archer-Daniels-Midland Company Transformation systems for flavinogenic yeast
CA2415473A1 (en) 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2002088317A2 (en) 2001-05-01 2002-11-07 The Regents Of The University Of California Fusion molecules and methods for treatment of immune diseases
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2633595A1 (en) 2001-06-20 2003-01-03 Genentech, Inc. Antibodies against tumor-associated antigenic target (tat) polypeptides
CA2458670C (en) 2001-08-29 2016-08-23 Genentech, Inc. Bv8 nucleic acids and polypeptides with mitogenic activity
CA2460120A1 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
JP2005528905A (ja) 2002-06-07 2005-09-29 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
US7252933B2 (en) 2002-06-26 2007-08-07 Flanders Interuniversity Institute For Biotechnology Protein glycosylation modification in methylotrophic yeast
PL214010B1 (pl) 2002-07-15 2013-06-28 Genentech Inc Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala
EP1578373A4 (en) 2002-09-11 2007-10-24 Genentech Inc NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
DK2332996T3 (en) 2002-09-11 2014-12-15 Genentech Inc Purification of anti-Her2 antibodies
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISEASES
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
EP1576137A4 (en) 2002-10-29 2010-06-30 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP2308968A1 (en) 2002-11-26 2011-04-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
DE60335602D1 (de) * 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
ATE387494T1 (de) * 2002-12-20 2008-03-15 Hoffmann La Roche Hitzelabile desoxyribonuklease i-varianten
AU2004205684A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7332299B2 (en) 2003-02-20 2008-02-19 Glycofi, Inc. Endomannosidases in the modification of glycoproteins in eukaryotes
CN102225194B (zh) 2003-03-12 2014-07-16 健泰科生物技术公司 Bv8和/或EG-VEGF促进造血的用途
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
ZA200507757B (en) 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
MXPA05012723A (es) 2003-05-30 2006-02-08 Genentech Inc Tratamiento con anticuerpos anti-vgf.
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
PL1641822T3 (pl) 2003-07-08 2013-10-31 Genentech Inc Heterologiczne polipeptydy IL-17 A/F i ich zastosowania terapeutyczne
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2536635C (en) 2003-08-25 2015-05-12 Funzyme Biotechnologies Sa Novel fungal proteins and nucleic acids encoding same
NZ576411A (en) 2003-11-17 2010-04-30 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin
JP4411192B2 (ja) * 2003-12-05 2010-02-10 エフ．ホフマン−ラ ロシュ アーゲー 組換えで発現されるカルボキシペプチダーゼｂおよびその精製
SI2311873T1 (sl) 2004-01-07 2018-12-31 Novartis Vaccines And Diagnostics, Inc. M-CSF-specifična monoklonska protitelesa in njihova uporaba
US20070281332A1 (en) 2004-02-13 2007-12-06 Allan Svendsen Protease Variants
SI1730191T1 (sl) 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
DK1771474T3 (da) 2004-07-20 2010-05-31 Genentech Inc Inhibitorer af angiopoitin-like 4 protein, kombinationer og anvendelser deraf
US20090136490A1 (en) 2004-11-10 2009-05-28 Diadexus, Inc. Ovr110 antibody compositions and methods for use
DE602006013275D1 (de) 2005-01-07 2010-05-12 Diadexus Inc Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
RU2290434C1 (ru) * 2005-06-02 2006-12-27 Общество с ограниченной ответственностью "БиоГениус" Штамм дрожжей pichia pastoris 2-2 - продуцент тромбоцитарного фактора роста человека (pdgf-bb) и способ получения тромбоцитарного фактора роста человека
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
AU2006280321A1 (en) 2005-08-15 2007-02-22 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
KR101304958B1 (ko) * 2005-09-14 2013-09-17 에프. 호프만-라 로슈 아게 트립신 변이체에 의한 인슐린 전구체의 절단
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
EP1948798B1 (en) 2005-11-18 2015-04-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
CA2638821A1 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
WO2007109376A2 (en) 2006-03-23 2007-09-27 Novartis Ag Anti-tumor cell antigen antibody therapeutics
NZ571479A (en) 2006-04-05 2012-10-26 Abbott Biotech Ltd Antibody purification
EP2614839A3 (en) 2006-04-05 2015-01-28 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
EP2010662A2 (en) 2006-04-19 2009-01-07 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US8592149B2 (en) 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
JP2009537147A (ja) 2006-05-15 2009-10-29 シー レーン バイオテクノロジーズ， エルエルシー インフルエンザウイルスに対する中和抗体
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
ES2531933T3 (es) 2006-06-30 2015-03-20 Novo Nordisk A/S Anticuerpos anti-NKG2A y usos de los mismos
KR101368596B1 (ko) 2006-08-18 2014-03-17 조마 테크놀로지 리미티드 Ｐｒｌｒ 특이적 항체 및 그 용도
JP5503968B2 (ja) 2006-09-27 2014-05-28 ノボ・ノルデイスク・エー／エス 成熟インスリンポリペプチドの作製方法
PT2087002E (pt) 2006-10-27 2014-11-26 Lpath Inc Composições e métodos para a ligação de esfingosina-1- fosfato
US8614103B2 (en) 2006-10-27 2013-12-24 Lpath, Inc. Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
JP5519287B2 (ja) 2006-11-02 2014-06-11 ダニエル・ジェイ・カポン 可動部を備えたハイブリッド免疫グロブリン
ES2437110T3 (es) 2006-11-14 2014-01-08 Genentech, Inc. Moduladores de la regeneración neuronal
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
JP5391073B2 (ja) 2006-11-27 2014-01-15 ディアデクサス インコーポレーテッド Ｏｖｒ１１０抗体組成物および使用方法
US8288110B2 (en) * 2006-12-04 2012-10-16 Perkinelmer Health Sciences, Inc. Biomarkers for detecting cancer
EP2101816B1 (en) 2006-12-07 2013-08-14 Novartis AG Antagonist antibodies against ephb3
NZ577933A (en) 2007-01-22 2011-12-22 Genentech Inc Polyelectrolyte precipitation and purification of antibodies
US20100144599A1 (en) 2007-02-02 2010-06-10 Bristol-Myers Squibb Company Vegf pathway blockade
DK2140021T3 (da) 2007-02-22 2012-05-07 Genentech Inc Fremgangsmåder til detektion af inflammatorisk tarmsygdom.
DK2134853T3 (en) 2007-04-03 2018-10-08 Oxyrane Uk Ltd Glycosylation of molecules
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CA2724432A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
CN101809034B (zh) 2007-06-07 2015-07-08 健泰科生物技术公司 C3b抗体及用于预防和治疗补体相关病症的方法
EP4365189B1 (en) 2007-07-09 2025-02-19 F. Hoffmann-La Roche AG Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PL2474557T3 (pl) 2007-07-16 2015-02-27 Genentech Inc Przeciwciała anty- CD79b i immunokoniugaty i sposoby stosowania
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
US8361465B2 (en) 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
DK2215117T4 (en) 2007-10-30 2018-04-09 Genentech Inc ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
WO2009061910A1 (en) 2007-11-08 2009-05-14 Genetech, Inc. Anti-factor b antibodies and their uses
DK2220116T3 (da) 2007-11-12 2012-11-26 Theraclone Sciences Inc Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
AR070141A1 (es) 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CA2712220A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
NZ587132A (en) 2008-01-31 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
BRPI0910286A2 (pt) * 2008-03-03 2015-09-29 Abbott Lab métodos para transformação de levedura
US7982012B2 (en) 2008-03-10 2011-07-19 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of cytomegalovirus
JP2011516423A (ja) 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
PE20141549A1 (es) 2008-05-06 2014-10-25 Genentech Inc VARIANTES DE CRIg MADURAS POR AFINIDAD
CA2726804C (en) 2008-06-02 2021-12-28 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
EP2321337B2 (en) 2008-08-14 2018-10-10 Genentech, Inc. Methods for removing a contaminant using protein displacement ion exchange membrane chromatography
WO2010034015A2 (en) 2008-09-22 2010-03-25 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
AU2009308293B2 (en) 2008-10-22 2015-02-05 Genentech, Inc. Modulation of axon degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
EP2346903A1 (en) 2008-11-06 2011-07-27 Glenmark Pharmaceuticals S.A. Treatment with anti-alpha2 integrin antibodies
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
KR101544245B1 (ko) 2009-02-03 2015-08-12 아뮤닉스 오퍼레이팅 인코포레이티드 연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
SI3260136T1 (sl) 2009-03-17 2021-05-31 Theraclone Sciences, Inc. Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
RU2587621C2 (ru) 2009-04-01 2016-06-20 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US20100297127A1 (en) 2009-04-08 2010-11-25 Ghilardi Nico P Use of il-27 antagonists to treat lupus
WO2010124163A2 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
US8858948B2 (en) 2009-05-20 2014-10-14 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
CN103140236B (zh) 2009-06-08 2017-04-19 阿穆尼克斯运营公司 生长激素多肽及其制备和使用方法
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
EP2454373B1 (en) 2009-07-15 2014-11-19 AbbVie Inc. Enhancement of cellular production through mechanotransduction
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
EP2473617B1 (en) 2009-09-01 2020-02-26 F.Hoffmann-La Roche Ag Enhanced protein purification through a modified protein a elution
AU2010289400B2 (en) 2009-09-02 2014-10-23 Curis, Inc. Mutant smoothened and methods of using the same
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
BR112012007099A2 (pt) 2009-09-29 2015-09-15 Oxyrane Uk Ltd hidrólise da ligação manose-1-fosfo-6-manose a fosfo-manose
EP2488643A4 (en) 2009-10-15 2013-07-03 Hoffmann La Roche CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY
CN104744560A (zh) 2009-10-20 2015-07-01 Abbvie公司 使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
RU2012120783A (ru) 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
US20110098862A1 (en) 2009-10-27 2011-04-28 ExxonMobil Research Engineering Company Law Department Multi-stage processes and control thereof
MX2012005464A (es) 2009-11-12 2012-06-08 Genentech Inc Un metodo para promover la densidad de espinas dendriticas.
CA2781240A1 (en) 2009-11-19 2011-05-26 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
EP3002297B1 (en) 2009-11-30 2020-04-08 F. Hoffmann-La Roche AG Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211)
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
CN102666568B (zh) 2009-12-18 2015-12-09 杰特有限公司 纯化多肽的方法
AU2010334383B2 (en) 2009-12-21 2014-10-02 Centre Hospitalier Universitaire Vaudois (Chuv) Synergic action of a prolyl protease and tripeptidyl proteases
EP2515941B1 (en) 2009-12-21 2019-11-13 F.Hoffmann-La Roche Ag Pharmaceutical formulation of bevacizumab
CN102812046B (zh) 2010-01-28 2015-02-25 葛兰素集团有限公司 Cd127结合蛋白
TWI429453B (zh) 2010-02-23 2014-03-11 建南德克公司 抗tat419抗體及其用途
RU2545401C2 (ru) 2010-02-23 2015-03-27 Санофи Антитела к интегрину альфа-2 и их применения
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
DK2796467T3 (en) 2010-03-31 2018-05-07 Boehringer Ingelheim Int Anti-CD40 antibodies
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
MX342239B (es) 2010-05-03 2016-09-21 Genentech Inc * Composiciones y metodos para el diagnostico y tratamiento de tumores.
MX343604B (es) 2010-05-28 2016-11-11 Genentech Inc Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
AU2011261161A1 (en) 2010-06-01 2013-01-10 Ludwig Institute For Cancer Research Limited Antibodies directed to the unprocessed receptor tyrosine kinase c-Met
TW201210612A (en) 2010-06-03 2012-03-16 Glaxo Group Ltd Humanised antigen binding proteins
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
CN103108887A (zh) 2010-07-22 2013-05-15 葛兰素史密丝克莱恩生物有限公司 新的抗原结合蛋白
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
CA2807664A1 (en) 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
CA3059961C (en) 2010-08-31 2021-04-13 Theraclone Sciences, Inc. Human immunodeficiency virus (hiv)-neutralizing antibodies
AU2011302522A1 (en) 2010-09-15 2013-05-02 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
CN105753933A (zh) 2010-09-20 2016-07-13 Abbvie 公司 采用模拟移动床色谱纯化抗体
JP6151183B2 (ja) 2010-09-29 2017-06-21 オキシレイン ユーケー リミテッド マンノース−１−ホスホ−６−マンノース結合からキャップを外すことおよびリン酸化ｎ−グリカンを脱マンノシル化することができるマンノシダーゼならびに哺乳動物細胞による糖タンパク質の取り込みを促進する方法
US9689015B2 (en) 2010-09-29 2017-06-27 Oxyrane Uk Limited De-mannosylation of phosphorylated N-glycans
CA2813738A1 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CA2814030C (en) 2010-10-08 2019-04-30 Shanghai Kexin Biotech Co., Ltd. Diagnostic and therapeutic uses of moesin fragments
EP2624851B1 (en) 2010-10-08 2016-11-30 Shanghai Kexin Biotech Co., Ltd Moesin fragments and uses thereof
EP2624855B1 (en) 2010-10-08 2016-12-14 Shanghai Kexin Biotech Co., Ltd Moesin fragments associated with aplastic anemia
WO2012045274A1 (en) 2010-10-08 2012-04-12 Shanghai Kexin Biotech Co., Ltd. Moesin modulators and uses thereof
CA2814029C (en) 2010-10-08 2017-05-09 Shanghai Kexin Biotech Co., Ltd. Moesin fragments associated with immune thrombocytopenia
HRP20161141T1 (hr) 2010-11-04 2016-12-02 Boehringer Ingelheim International Gmbh Anti-il-23 protutijela
SG10201407036YA (en) 2010-11-05 2014-12-30 Transbio Ltd Markers of Endothelial Progenitor Cells and Uses Thereof
US9068970B2 (en) 2010-11-05 2015-06-30 Abbvie Inc. Efficient and effective supplement screening for the development of chemically defined media in cell culture
WO2012064619A1 (en) * 2010-11-10 2012-05-18 Merck Sharp & Dohme Corp. Pichia pastoris loci encoding enzymes in the proline biosynthetic pathway
WO2012099566A1 (en) 2010-11-17 2012-07-26 Sea Lane Biotechnologies, Llc Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
CN103429261A (zh) 2010-12-22 2013-12-04 塞法隆澳大利亚股份有限公司 半寿期改进的修饰抗体
CA2827301A1 (en) 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CN103619876A (zh) 2011-03-10 2014-03-05 Hco抗体股份有限公司 双特异性三链抗体样分子
US20120238730A1 (en) 2011-03-15 2012-09-20 Abbott Laboratories Integrated approach to the isolation and purification of antibodies
EP2685968A1 (en) 2011-03-15 2014-01-22 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
TW201239355A (en) 2011-03-23 2012-10-01 Abbott Lab Methods and systems for the analysis of protein samples
WO2012135589A1 (en) 2011-03-31 2012-10-04 Genentech, Inc. Methods of administering beta7 integrin antagonists
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2710042A2 (en) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
JP2013040160A (ja) 2011-07-01 2013-02-28 Genentech Inc 自己免疫疾患を治療するための抗ｃｄ８３アゴニスト抗体の使用
JP6261499B2 (ja) 2011-07-11 2018-01-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｏｘ４０と結合する抗体およびその使用
BR112014003599A2 (pt) 2011-08-17 2018-04-17 Genentech Inc método de inibição da angiogênese tumoral, método de supressão do crescimento tumoral e método de tratamento de tumor
US8822651B2 (en) 2011-08-30 2014-09-02 Theraclone Sciences, Inc. Human rhinovirus (HRV) antibodies
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
LT2780373T (lt) 2011-11-16 2019-09-25 Boehringer Ingelheim International Gmbh Anti il-36r antikūnai
ES2651521T3 (es) 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
CA2859556C (en) 2011-12-16 2022-01-11 Braskem S.A. Modified microorganisms and methods of making butadiene using same
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
TR201815709T4 (tr) 2011-12-22 2018-11-21 Hoffmann La Roche İyon değişim membranı kromatografisi.
JP2015503338A (ja) 2011-12-30 2015-02-02 オキシレイン ユーケー リミテッド 組換えタンパク質の分解を低減させる方法および材料
MX357071B (es) 2012-01-19 2018-06-22 Univ Cincinnati Medicamentos que comprenden apolipoproteína a-iv no glicosilada para el tratamiento de diabetes.
JP2015506950A (ja) 2012-01-31 2015-03-05 ジェネンテック， インコーポレイテッド 抗ｉｇ−ｅｍ１’抗体およびそれを用いる方法
CA2864177C (en) 2012-03-01 2019-11-26 Amgen Research (Munich) Gmbh Prolonged half-life albumin-binding protein fused bispecific antibodies
KR102028228B1 (ko) 2012-03-15 2019-10-04 옥시레인 유케이 리미티드 폼페병의 치료를 위한 방법 및 물질
WO2013158275A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Cell culture methods to reduce acidic species
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
DK2841087T3 (da) 2012-04-27 2017-11-20 Us Health Vaskulær endothel-vækstfaktor-antagonister og fremgangsmåder til anvendelse deraf
CN109206516A (zh) 2012-05-03 2019-01-15 勃林格殷格翰国际有限公司 抗IL-23p19抗体
TW201348246A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之人類、人類化或嵌合抗體之新穎純化
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
WO2014018763A2 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating type i diabetes using apolipoprotein aiv
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
JP6374392B2 (ja) 2012-11-05 2018-08-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｘｂｐ１、ｃｄ１３８およびｃｓ１ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
EP2941302B1 (en) 2013-01-02 2018-08-01 Glenmark Pharmaceuticals S.A. Antibodies that bind to tl1a and their uses
EP2948478B1 (en) 2013-01-25 2019-04-03 Amgen Inc. Antibodies targeting cdh19 for melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20190040368A1 (en) 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
RU2707092C2 (ru) 2013-03-13 2019-11-22 Дженентек, Инк. Составы со сниженным окислением
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
MY189047A (en) 2013-03-13 2022-01-21 Genentech Inc Antibody formulations
US10653779B2 (en) 2013-03-13 2020-05-19 Genentech, Inc. Formulations with reduced oxidation
ES2808823T3 (es) 2013-03-13 2021-03-02 Hoffmann La Roche Formulaciones con oxidación reducida
WO2014151901A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
KR20150129033A (ko) 2013-03-14 2015-11-18 애브비 인코포레이티드 저 산성 종 조성물 및 이의 제조 및 사용 방법
HK1213919A1 (zh) 2013-03-14 2016-07-15 Abbvie Inc. 低酸性物質組合物和利用置換色譜技術製備該組合物的方法
WO2014142882A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Protein purification using displacement chromatography
RU2015144020A (ru) 2013-03-15 2017-04-21 Дженентек, Инк. Среды для культивирования клеток и способы получения антител
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
DK2968495T3 (da) 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
AR095596A1 (es) 2013-03-15 2015-10-28 Amgen Res Munich Gmbh Moléculas de unión de cadena única comprendiendo n-terminal abp
KR102235452B1 (ko) 2013-03-15 2021-04-02 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
US10233249B2 (en) 2013-03-19 2019-03-19 Beijing Shenogen Pharma Group Ltd. Antibodies and methods for treating estrogen receptor-associated diseases
EP3933401A3 (en) 2013-03-27 2022-04-13 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
HK1220982A1 (zh) 2013-05-31 2017-05-19 基因泰克公司 抗壁磷壁酸抗體和綴合物
JP2016521701A (ja) 2013-06-07 2016-07-25 ノヴォ ノルディスク アー／エス 成熟インスリンポリペプチドを作製するための方法
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
ES2768614T3 (es) 2013-09-27 2020-06-23 Hoffmann La Roche Formulaciones de anticuerpos anti-PDL1
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
EP3647324A1 (en) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN106062005A (zh) 2013-12-30 2016-10-26 医药生命融合研究团 抗krs单克隆抗体及其用途
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
BR112016014731A2 (pt) 2014-01-31 2017-09-19 Boehringer Ingelheim Int Anticorpos anti-baff
DK3102197T3 (en) 2014-02-04 2018-11-19 Genentech Inc Smoothened mutant and methods for its use
SI3116486T1 (sl) 2014-03-14 2020-07-31 Biomolecular Holdings Llc Hibridni imunoglobulin, ki vsebuje nepeptidilno vezavo
CN111808276A (zh) 2014-03-25 2020-10-23 豪夫迈·罗氏有限公司 制备用于细胞培养基中的泊洛沙姆的方法
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
US8961992B1 (en) 2014-04-02 2015-02-24 Tunitas Therapeutics, Inc. Epsigam fusion protein
EP3149187B1 (en) 2014-05-30 2020-04-29 Braskem S.A. Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
US20170183376A1 (en) 2014-06-24 2017-06-29 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
WO2016004197A1 (en) 2014-07-03 2016-01-07 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
US11661462B2 (en) 2014-07-31 2023-05-30 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody contructs
KR20170057339A (ko) 2014-09-15 2017-05-24 제넨테크, 인크. 항체 제형
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
JP2017537090A (ja) 2014-11-17 2017-12-14 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
CA2965540A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof
WO2016120764A1 (en) 2015-01-26 2016-08-04 Centre Hospitalier Universitaire Vaudois (Chuv) Aspergillus oryzae prolyl endopeptidases and use thereof in degradation of polypeptides
KR20170120616A (ko) 2015-02-04 2017-10-31 베링거 인겔하임 인터내셔날 게엠베하 염증성 질환의 치료 방법
AU2016215227A1 (en) 2015-02-04 2017-09-21 Assistance Publique-Hopitaux De Paris Mutant smoothened and methods of using the same
MX2017010336A (es) 2015-02-26 2017-12-20 Genentech Inc Antagonistas de integrina beta7 y métodos para el tratamiento de la enfermedad de crohn.
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
KR20170135972A (ko) 2015-04-14 2017-12-08 베링거 인겔하임 인터내셔날 게엠베하 질환을 치료하는 방법
PL3283524T3 (pl) 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
EP3763827A1 (en) 2015-05-29 2021-01-13 F. Hoffmann-La Roche AG Pd-l1 promoter methylation in cancer
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
HUE068751T2 (hu) 2015-08-11 2025-01-28 Wuxi Biologics Ireland Ltd Új anti-PD-1 ellenanyagok
ES2862175T3 (es) 2015-09-07 2021-10-07 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Receptor de tipo IGFR novedoso y usos del mismo
TWI811716B (zh) 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2017109034A1 (en) 2015-12-24 2017-06-29 Oxyrane Uk Ltd Human alpha-n-acetylgalactosaminidase polypeptide
JP7008023B2 (ja) 2015-12-30 2022-01-25 ジェネンテック， インコーポレイテッド 低減されたポリソルベート分解を有する製剤
KR20180093078A (ko) 2015-12-30 2018-08-20 제넨테크, 인크. 단백질 제제를 위한 트립토판 유도체의 용도
TN2018000263A1 (en) 2016-02-03 2020-01-16 Amgen Inc BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
IL260920B (en) 2016-02-03 2022-09-01 Amgen Res Munich Gmbh Constructs of psma and cd3 bispecific antigens that bind to t-cells, preparations containing them and uses thereof
CN109071625A (zh) 2016-02-04 2018-12-21 柯瑞斯公司 平滑化突变体和其使用方法
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
EP3433277A4 (en) 2016-03-23 2020-06-17 Mabspace Biosciences (Suzhou) Co., Ltd NEW ANTI-PD-L1 ANTIBODIES
ES2930351T3 (es) 2016-04-15 2022-12-09 Evive Biotechnology Shanghai Ltd Un dímero de IL-22 para su uso en el tratamiento de enterocolitis necrosante
EP3974451A3 (en) 2016-04-15 2022-07-06 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
WO2017207694A1 (en) 2016-06-02 2017-12-07 Kohlmann Angelica Antibodies that bind to human anti-müllerian hormone (amh) and their uses
US10519250B2 (en) 2016-08-01 2019-12-31 Xoma (Us) Llc Parathyroid hormone receptor 1 (PTH1R) antibodies and uses thereof
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
JP2020502991A (ja) 2016-09-20 2020-01-30 ウーシー バイオロジクス アイルランド リミテッド 新規抗ｐｃｓｋ９抗体
US10858428B2 (en) 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
JP2019536756A (ja) 2016-10-14 2019-12-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
WO2018138376A1 (en) 2017-01-30 2018-08-02 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel igfr-like 2 receptor and uses thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
WO2018166495A1 (en) 2017-03-15 2018-09-20 Tsinghua University Novel anti-trkb antibodies
WO2018182284A1 (ko) 2017-03-27 2018-10-04 재단법인 의약바이오컨버젼스연구단 세포 외막에 노출되는 라이실-tRNA 합성효소 N-말단 영역에 특이적으로 결합하는 항체
CN110461877A (zh) 2017-03-27 2019-11-15 勃林格殷格翰国际有限公司 抗il-36r抗体联合治疗
US11236151B2 (en) 2017-04-25 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
SG11201909547TA (en) 2017-05-05 2019-11-28 Amgen Inc Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
AU2018326805B2 (en) 2017-09-01 2023-11-30 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to BCMA and TACI antigens for treatment of cancer
SG11202002508XA (en) 2017-09-22 2020-04-29 Wuxi Biologics Ireland Ltd Novel bispecific cd3/cd19 polypeptide complexes
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
EP3724229A1 (en) 2017-12-11 2020-10-21 Amgen Inc. Continuous manufacturing process for bispecific antibody products
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
AU2019223076A1 (en) 2018-02-21 2020-10-08 Celgene Corporation BCMA-binding antibodies and uses thereof
EP3768725A4 (en) 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
KR102340989B1 (ko) 2018-03-28 2021-12-20 에이비온 주식회사 클라우딘 3의 ecl-2에 특이적으로 결합하는 항체, 이의 단편 및 이들의 용도
CN112334485B (zh) 2018-04-06 2024-09-27 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
WO2019213416A1 (en) 2018-05-02 2019-11-07 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
SG11202012446UA (en) 2018-06-23 2021-01-28 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
JP7504808B2 (ja) 2018-06-29 2024-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫疾患の処置における使用のための抗ｃｄ４０抗体
SG11202100601TA (en) 2018-08-08 2021-02-25 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
JP7548587B2 (ja) 2018-09-07 2024-09-10 アイタブメッド （エイチケイ） リミテッド 二重特異性抗原結合タンパク質及びその使用
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
CN113365697B (zh) 2018-09-25 2024-07-19 百进生物科技公司 抗tlr9药剂和组合物及其制备方法和使用方法
JP7596260B2 (ja) 2018-09-28 2024-12-09 アムジエン・インコーポレーテツド 可溶性ｂｃｍａに対する抗体
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
AU2019365391A1 (en) 2018-10-23 2021-04-29 Consejo Superior De Investigaciones Científicas Antibodies specific for glycosylated ApoJ and uses thereof
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
US12448429B2 (en) 2019-03-06 2025-10-21 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
WO2020197400A1 (en) 2019-03-27 2020-10-01 Umc Utrecht Holding B.V. Engineered iga antibodies and methods of use
AR122266A1 (es) 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
CA3141504A1 (en) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
TWI877179B (zh) 2019-06-27 2025-03-21 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
WO2021054778A1 (ko) 2019-09-20 2021-03-25 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
US20220396599A1 (en) 2019-11-13 2022-12-15 Amgen Inc. Method for Reduced Aggregate Formation in Downstream Processing of Bispecific Antigen-Binding Molecules
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
AU2021236302A1 (en) 2020-03-12 2022-10-20 Immune-Onc Therapeutics, Inc. Novel anti-LILRB4 antibodies and derivative products
CN113461817B (zh) 2020-03-31 2025-04-18 苏州泽璟生物制药股份有限公司 一种抗人cd47抗体及其抗原结合片段、制备方法和应用
CN115397970A (zh) 2020-04-15 2022-11-25 基因泰克公司 铜损失减轻
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
KR102871588B1 (ko) 2020-05-26 2025-10-17 베링거 인겔하임 인터내셔날 게엠베하 항-pd-1 항체
AR122493A1 (es) 2020-06-02 2022-09-14 Arcus Biosciences Inc Anticuerpos anti-tigit
US12391745B2 (en) 2020-06-15 2025-08-19 Sarepta Therapeutics, Inc. Adeno-associated virus antibodies and fragments thereof
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
EP3939999A1 (en) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
AR124017A1 (es) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh Polipéptidos con perfil de recorte potenciado
EP4240770A1 (en) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptide constructs selectively binding to cldn6 and cd3
US20230406929A1 (en) 2020-11-06 2023-12-21 Amgen Inc. Polypeptide constructs binding to cd3
CN112480248B (zh) 2020-11-24 2023-05-05 三优生物医药(上海)有限公司 与cld18a2特异性结合的分子
KR20230132470A (ko) 2020-12-18 2023-09-15 키닉사 파마슈티컬스, 리미티드 단백질 조성물 및 이를 생산하는 방법 및 사용하는방법
JP2024513376A (ja) 2021-04-02 2024-03-25 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
WO2022228422A1 (zh) 2021-04-26 2022-11-03 轩竹生物科技股份有限公司 一种双特异抗体偶联物
US20240343789A1 (en) 2021-07-23 2024-10-17 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Igfr-l1 antibodies and uses thereof
EP4444281A1 (en) 2021-12-10 2024-10-16 Tubulis GmbH Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
IL313655A (en) 2021-12-22 2024-08-01 Boehringer Ingelheim Int Anti-C3 antibodies and their antigen-binding fragments and their uses for the treatment of eyes or eye diseases
KR20230098953A (ko) 2021-12-27 2023-07-04 경북대학교 산학협력단 Asm에 특이적으로 결합하는 항체 및 이의 용도
EP4471138A1 (en) 2022-01-29 2024-12-04 Peking University First Hospital Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof
EP4238988A1 (en) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Antibodies against sars-cov-2 and uses thereof
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
WO2024032891A1 (en) 2022-08-11 2024-02-15 Vib Vzw Glyco-engineered yeast for therapeutic protein production
JP2025529896A (ja) 2022-08-22 2025-09-09 アブデラ セラピューティクス インク． Ｄｌｌ３結合分子およびその使用
TW202421650A (zh) 2022-09-14 2024-06-01 美商安進公司 雙特異性分子穩定組成物
KR20250090330A (ko) 2022-10-18 2025-06-19 투불리스 게엠베하 신규한 항-tpbg 항체 및 이를 기반으로 한 항체-약물-접합체, 치료 방법 및 이의 용도
EP4605012A2 (en) 2022-10-18 2025-08-27 Tubulis GmbH Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
EP4640708A1 (en) 2022-12-23 2025-10-29 Chimagen Biosciences, Ltd Novel anti-gprc5d antibody
JP2025542322A (ja) 2022-12-23 2025-12-25 チマゲン・バイオサイエンシズ，リミテッド Ｇｐｒｃ５ｄを標的とする多重特異性ポリペプチド複合物
CN121152803A (zh) 2023-05-25 2025-12-16 百进公司 Ceacam6结合抗体和其抗原结合片段
UY40797A (es) 2023-06-14 2024-12-31 Amgen Inc Moléculas captadoras de enmascaramiento de células t
WO2025036848A1 (en) 2023-08-11 2025-02-20 Wuxi Biologics (Shanghai) Co., Ltd. Anti-muc16 antibodies and uses thereof
WO2025043134A1 (en) 2023-08-24 2025-02-27 Rezolute, Inc. High concentration formulations for anti-insulin receptor antibody and uses thereof
WO2025072313A1 (en) 2023-09-27 2025-04-03 BioLegend, Inc. Anti-gpc4 antibodies
TW202523694A (zh) 2023-11-17 2025-06-16 中國大陸商上海藥明生物技術有限公司 抗muc16抗體及其用途
WO2025144974A1 (en) 2023-12-29 2025-07-03 Absci Corporation Half-life extending fc domain variants and uses thereof
WO2025157132A1 (en) 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof
WO2025171378A1 (en) 2024-02-09 2025-08-14 Rezolute, Inc. Insulin receptor modulation for tumor associated hyperinsulinism
WO2025212738A1 (en) 2024-04-04 2025-10-09 BioLegend, Inc. Chi3l1 binding antibodies and antigen binding fragments thereof
WO2025230843A2 (en) 2024-05-01 2025-11-06 BioLegend, Inc. Kir binding antibodies and antigen binding fragments thereof
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition
WO2026006472A2 (en) 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Compositions of il-1r1 antibodies and methods of producing and using the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068969B (en) * 1980-02-05 1983-07-27 Upjohn Co Gene expression
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4617274A (en) * 1981-10-29 1986-10-14 Phillips Petroleum Company Biochemical conversions by yeast fermentation at high cell densities
IL68733A (en) * 1982-05-19 1989-01-31 Gist Brocades Nv Kluyveromyces cells transformed by a dna sequence encoding a polypeptide,expression vectors containing said dna sequence and process for the transformation of kluyveromyces cells by said vector
NO840200L (no) * 1983-01-28 1984-07-30 Cefus Corp Glukoamylase cdna.
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia

Also Published As

Publication number Publication date
SG43092G (en) 1992-06-12
EP0183070B1 (en) 1991-10-09
JPS61108383A (ja) 1986-05-27
MX430A (es) 1993-11-01
AU572353B2 (en) 1988-05-05
DE3584353D1 (de) 1991-11-14
FI94428B (fi) 1995-05-31
PT81402B (pt) 1987-11-11
JPH0681593B2 (ja) 1994-10-19
US4879231A (en) 1989-11-07
AU4875685A (en) 1986-06-12
ATE68204T1 (de) 1991-10-15
EP0183070A3 (en) 1987-09-30
ES548306A0 (es) 1986-09-01
FI94428C (fi) 1995-09-11
IE852473L (en) 1986-04-30
EP0183070A2 (en) 1986-06-04
IE58217B1 (en) 1993-08-11
ZA858180B (en) 1986-06-25
GR852609B (OSRAM) 1986-03-04
PT81402A (en) 1985-11-01
IL76763A (en) 1991-03-10
CA1297438C (en) 1992-03-17
NO178975B (no) 1996-04-01
FI854145L (fi) 1986-05-01
DK496485D0 (da) 1985-10-29
ES8609464A1 (es) 1986-09-01
FI854145A0 (fi) 1985-10-23
NO178975C (no) 1996-07-10
IL76763A0 (en) 1986-02-28
NO854334L (no) 1986-05-02

Similar Documents

Publication Publication Date Title
DK496485A (da) Transformation af gaer-stammer af slaegten pichia
ATE54167T1 (de) Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
ES518348A0 (es) Un plasmido vector recombinante.
EP0188677A3 (en) Genes from pichia histidine pathway and uses thereof
DK459989A (da) Fremgangsmaade til fremstilling af 2-keto-l-gulonsyre
ATE81136T1 (de) Immunogenes produkt, erhalten durch expression in einer rekombinanten hefe, und verfahren zu seiner reinigung.
AU6279390A (en) Multi-functional enzymes including derivable 2',3'-didesoxyribofuranoside triphoshpates
PT80174A (en) Process for the preparation of n1-methyl-10alpha-methoxylumilysergol and esters thereof and intermediates for their preparation
PT81052B (pt) Processo de preparacao de saccharomyces recombinantes
EP0076696A3 (en) A restriction enzyme and a method for production thereof
EP0112012A3 (en) Recombinant DNA molecules
EP0285361A3 (en) Purification of apase-1 1 and retrieval of the nematode resistance gene
EP0176916A3 (en) Process for production of gamma-interferon
WO1994011518A3 (en) Methods for converting a, ab, and b blood types to o blood type
CA2002480A1 (en) Process for the production of human lysozyme
IE43702L (en) Obtaining e. coli enterotoxin
DK0592574T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner og værtsceller anvendt derved
KR950018453A (ko) 콜라게네이즈 인지부위를 가진 재조합 인간 성장 호르몬

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment